151
|
Jhaveri K, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, Friedman K, Neville D, Esteva F, Hudis C, Modi S. Abstract P4-14-21: A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Targeted therapies in HER2+ MBC significantly improve outcomes but efficacy is limited by therapeutic resistance. HSP90 is a molecular chaperone involved in the stability and function of multiple signaling onco-proteins. HER2 is an acutely sensitive HSP90 client and HSP90 inhibition can overcome trastuzumab resistance. Our group reported objective responses with 17-AAG plus trastuzumab in HER2+ MBC. Ganetespib, a synthetic, second generation HSP90 inhibitor has increased potency and tolerability compared with earlier agents. We reported anti-tumor activity in metastatic HER2+ and triple negative breast cancer with single agent ganetespib. Preclinically, HSP90 inhibition has synergistic anti-tumor activity with taxanes and trastuzumab. This study will define the MTD and RP2D of ganetespib plus paclitaxel and trastuzumab in HER2+ MBC.
Methods: In this 3+3 phase I dose escalation study, patients with trastuzumab-resistant HER2+ MBC receive weekly trastuzumab and paclitaxel (80mg/m2) with ganetespib on day 1, 8, 15 of a 28 day cycle. HR+ positive patients are required to have at least one prior line of endocrine therapy. DLT of ganetespib monotherapy is diarrhea and therefore patients receive prophylactic anti-motility agents. Based on prior experience with ganetespib plus docetaxel in NSCLC, only 3 dose levels of ganetespib were explored: 100mg/m2, 150mg/m2 and a 3rd cohort of 125mg/m2, if needed. Secondary endpoints include evaluation of effects of ganetespib on the pharmacokinetics (PK) of paclitaxel and preliminary efficacy assessment.
Results: The dosing cohorts (100 mg/m2 (n=3) and 150 mg/m2 (n=6)) have been completed without any DLTs. Median age was 46 years (range 29-65), median prior lines of chemotherapy and anti-HER2 therapy were 3 (range 2-6) and 3 (range 2-4) respectively, including prior pertuzumab in 9/9 and T-DM1 in 8/9 patients. There were no grade 3/4 adverse events (AEs) related to ganetespib. Most common AEs related to ganetespib were diarrhea, fatigue, anemia and rash. Paclitaxel PK data available from 6/9 patients are not appreciably different from those reported in literature. Overall response rate was 25% (2/8 had PR in 150 mg/m2 cohort; 1 patient was not evaluable), SD in 63% (5/8), and clinical benefit rate (CR+PR+SD>24 weeks) was 50% (4/8). 3 patients remain on study.
Conclusion: The RP2D of ganetespib is 150mg/m2 in combination with paclitaxel and trastuzumab. The combination was safe and well tolerated. Updated PFS and PK data will be presented. Despite prior taxanes, pertuzumab and T-DM1, clinical activity of this triplet regimen in this heavily pre-treated cohort is very promising and together with our prior experience with 17-AAG plus trastuzumab and single agent ganetespib warrants further study in HER2+ MBC. A phase 2 trial is being planned in trastuzumab-refractory HER2+ MBC who have progressed on prior pertuzumab and T-DM1. Additionally, the protocol is amended to assess the safety of ganetespib in combination with paclitaxel, trastuzumab and pertuzumab in the first-line setting.
Citation Format: Jhaveri K, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, Friedman K, Neville D, Esteva F, Hudis C, Modi S. A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-21.
Collapse
Affiliation(s)
- K Jhaveri
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - E Teplinsky
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - S Chandarlapaty
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - D Solit
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - K Cadoo
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - J Speyer
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - G D'Andrea
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - S Adams
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - S Patil
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - S Haque
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - K Friedman
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - D Neville
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - F Esteva
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - C Hudis
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| | - S Modi
- Memorial Sloan Kettering Cancer Center, NY, NY; NYU Langone Medical Center, NY, NY
| |
Collapse
|
152
|
Gucalp A, Hudis C, Norton L, Patil S, Kurman MR, Eisner JR, Moore WR, Traina TA. Abstract OT2-01-03: A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot2-01-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
VT-464, an oral dual lyase-selective CYP17 inhibitor and AR antagonist (wild-type and mutated forms [e.g., F876L and T877A]), is in multiple Phase (Ph) 2 studies as treatment for men with castration-resistant prostate cancer (CRPC). VT-464 inhibits the growth of multiple BC cell lines in vitro including MCF7 (ER(+)/AR low), tamoxifen-resistant MCF7, and MDA-MB-453 (ER(-)/AR(+)) in a dose-dependent manner and with greater potency/efficacy than enzalutamide (submitted, Ellison et al., 2015). A subset of TNBC and most ER(+) BC express AR, making them potential targets for VT-464 since it directly inhibits both androgen/estrogen synthesis and AR transcriptional activity.
Objectives: The primary objective of Ph 1, now enrolling, is to establish the once-daily dose of VT-464 in women. Secondary objectives include safety, PK and efficacy endpoints, including determination of clinical benefit rate (CBR) which is the primary objective of Ph 2. Exploratory objectives include the determination of the extent of AR expression and signaling in breast tissue and to evaluate the relationship of expression with VT-464 effects on circulating tumor biomarkers, circulating hormones and clinical outcomes.
Study Design: This study is an open-label, single arm, Ph 1/2 study of VT-464 in women with AR(+) TNBC or ER(+)/HER2 normal unresectable locally advanced or metastatic BC. Ph 1 will follow a modified 3+3 Fibonacci design with cohort expansion to 6 patients following a single DLT in the first 28-days of treatment. Approximately 2-3 dose-levels will be explored in Ph 1. Ph 1 start dose will be the MTD for men with CRPC. AR(+) TNBC and ER(+)/HER2 BC cohorts will be expanded in Ph 2 using the MTD from Ph 1. Ph 2 will follow a Simon's two-stage design with pre-determined futility parameters. Eligible patients will have ER≥1% BC or AR≥1% (as determined by central IHC testing using the Dako antibody) TNBC. ER(+) patients must be postmenopausal and must have received at least 1 prior line of endocrine therapy. Additional eligibility criteria include: ≥ 18 years of age, ECOG PS ≤ 1, unresectable locally advanced or metastatic BC, available representative tumor specimen to enable correlative science.
Treatment Plan: Eligible patients will receive VT-464 once-nightly with dinner in a continuous dosing schedule. Adverse events and concomitant medications will be collected from the time of signing of informed consent until 30 days after end of study visit (EOS). Safety labs will be monitored monthly through EOS. Dense PK will be collected after the first dose of study drug in Ph 1 and single morning samples collected approximately every two cycles thereafter in Ph 1 and Ph 2 until EOS. Blood samples for steroids, circulating tumor DNA and circulating tumor cells will be collected through Cycle 2 and then at EOS. Tumor biopsy will be collected at baseline and at disease progression. Radiographic response will be assessed every 8 weeks and EOS.
Patient Accrual: Accrual is ongoing with 12-18 patients expected to be enrolled in Ph 1.
Citation Format: Gucalp A, Hudis C, Norton L, Patil S, Kurman MR, Eisner JR, Moore WR, Traina TA. A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT2-01-03.
Collapse
Affiliation(s)
- A Gucalp
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| | - C Hudis
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| | - L Norton
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| | - S Patil
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| | - MR Kurman
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| | - JR Eisner
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| | - WR Moore
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| | - TA Traina
- Breast Medicine Service, Memorial Sloan Kettering Cancer Center, NY, NY; Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, NY; Innocrin Pharmaceuticals, Inc., Durham, NC
| |
Collapse
|
153
|
Ghosh M, Sheela ML, Choudhury S, Bahadur U, Patil S, Satheesh CT, Murugan K, Nayak R, Sridhar PS, Rao N, Mahesh B, Shashidhara HP, Krishnamoorthy N, Gupta V, Sankaran S, Subramanian K, Ajaikumar BS. Abstract P6-07-01: Multigene profiling to identify clinically relevant actionable mutations in breast cancer: An Indian study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Numerous chemotherapeutic agents are available against breast cancer (BC), but a vast majority of patients diagnosed with this disease still develop treatment resistance and eventually succumb to disease. It remains an unmet need to identify specific molecular defects against which targeted therapy are available for improving clinical outcomes in BC. Our study aims to identify frequent hotspot mutations in BCs and determine their clinical impact.
Methods: 200 women with BC(early diagnosed and/or metastatic) aged 26-75 yrs (median age 50.5yrs) diagnosed at HCG from April 2013-15 were consented to be profiled by targeted deep sequencing for hotspot mutations in 48 cancer-related genes using Illumina's TSCAP panel and MiSeq technology in an IRB-approved prospective study in a CLIA compliant laboratory. All the cases had pathology review for stage, histological type, hormonal status and Ki67. The average coverage across 220 hot spots was greater than 1000X. Data was processed using Strand Avadis NGS™. Mutations identified in the tumor were assessed for 'actionability' i.e. response to therapy and impact on prognosis. Results: Somatic variants were detected in 75% of cases with direct impact on therapy or prognosis. Genetic aberrations were identified in PI3K/AKT/ mTOR signalling pathway in substantial fraction (27%) of breast cancer cases, out of which 17% had PIK3CA activating mutations,13 and 5 cases had PTEN and AKT deletions or truncating mutations respectively. Aberration in this pathway was more prevalent in HR+ve (53%) and HER2-ve including TNBC (61%) than in HR+/HER2+ve tumors (10.6%) of IDC histology. However, no correlation was found with stage and Ki67 index of the tumor. Notably 80% of BC cases presented with liver metastasis at the time of diagnosis were detected with PIK3CA mutation indicating its role as a surrogate marker of organ specific metastasis. PIK3CA was found to be co mutated with p53 in 16 cases (9%) of which 4 cases showed npCR post NACT. Also disruptive and non-disruptive mutations in TP53 alone were found in 25% of BC, varying widely among different histologies. A follow up of few cases showed shorter PFS and poor outcome in resected BC treated with NACT indicating its robust prognostic value in NACT setting. Furthermore, two patients were detected with cKIT mutations indicating sensitivity to imatinib and therefore enrolled on a clinical trial. The other variants were found in RB1(n=8),Her2 (n=2),FGFR amplification(n=1), KRAS(n=2),NRAS(n=3)CDH1(n=1),FBXW7(n=2) and EGFR(n=1).All these variants detected indicated resistance to conventional therapy and suggested sensitivity to available targeted therapy, either approved or in clinical trials. The response and outcome are being monitored in about 20 (10%) patients who have been enrolled in clinical trials and receiving mutation specific targeted therapy. Conclusions: This study confirms the utility of multigene profiling in early diagnosed and advanced BC patients, to stratify them on their molecular profile who could potentially benefit from targeted therapy. Prospective studies and randomized clinical trials are ongoing to confirm the independent prognostic and therapeutic value of the mutations in a larger cohort of Indian population.
Citation Format: Ghosh M, Sheela ML, Choudhury S, Bahadur U, Patil S, Satheesh CT, Murugan K, Nayak R, Sridhar PS, Rao N, Mahesh B, Shashidhara HP, Krishnamoorthy N, Gupta V, Sankaran S, Subramanian K, Ajaikumar BS. Multigene profiling to identify clinically relevant actionable mutations in breast cancer: An Indian study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-01.
Collapse
Affiliation(s)
- M Ghosh
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - ML Sheela
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - S Choudhury
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - U Bahadur
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - S Patil
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - CT Satheesh
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - K Murugan
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - R Nayak
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - PS Sridhar
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - N Rao
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - B Mahesh
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - HP Shashidhara
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - N Krishnamoorthy
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - V Gupta
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - S Sankaran
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - K Subramanian
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - BS Ajaikumar
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| |
Collapse
|
154
|
Singh JC, Sugarman S, Jones L, Boafo C, Patil S, Schweber S, Yu A, Argolo D, Modi S, Iyengar N, Smyth L, Norton L, Baselga J, Hudis C, Dang C. Abstract P1-14-17: Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-14-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Trastuzumab and pertuzumab (HP) with standard chemotherapy is approved for use in the neoadjuvant setting. We performed a retrospective analysis of patients (pts) treated with dose-dense doxorubicin and cyclophosphamide (AC) → paclitaxel, trastuzumab, pertuzumab (THP) in the neoadjuvant setting. Here we report the pathologic complete response (pCR) rate.
Methods:
We abstracted medical records of patients who were treated with pertuzumab-based therapy in the neoadjuvant setting from September 1, 2013 to March 1, 2015. Charts were analyzed for pt demographics, stage of breast cancer, pathology reports, surgical data, and information on systemic therapy.
Results:
Charts from 66 pts were reviewed; 60 pts were evaluable for pCR defined as absence of invasive disease in the breast, and 6 were not (3-no anthracycline, 1-incomplete chart, 1-no surgery yet, 1-metastatic). Median age was 47 years (range 28-68 years). Of 60 pts, 52 (86%) had operable breast cancer (T1-3, N0-1, M0) of which 7 had clinical stage I disease (T1N0)]; 7 (12%) had locally advanced disease (T2-3, N2-3, M0 or T4a-c, any N, M0), and 1 (2%) had inflammatory breast cancer (T4d, any N, M0). 49 (82%) and 11 (18%) had hormone receptor (HR)-positive and negative diseases, respectively. All patients had HER2-positive breast cancer defined as immunohistochemistry (IHC) 3+ and/or fluorescent in-situ hybridization (FISH) of > 2.0. 30 pts (50%) underwent mastectomy and lumpectomy, respectively. Out of 60 evaluable pts, 41 (68%) had pCR; 32/49 (65%) with HR-positive and 9/11 (82%) with HR-negative diseases had pCR, respectively. Overall 58/60 (97%) pts completed neoadjuvant therapy; 2 did not (1 developed Steven Johnson Syndrome after one cycle of AC and 1 developed pneumonitis after third weekly dose of T with HP).
Conclusions:
At our single center experience the pCR rate of dose dense AC→THP is high at 68 %. These data are similar to results seen in the TRYPHAENA study, and we await the results from the BERENICE trial evaluating pCR as a secondary endpoint.
Patient Demographics Age, years <4525 (42%)45-5419 (32%)>5516 (26%) ECOG Performace Status 031 (52%)129 (48%) Hormone receptor (HR) status HR+ Her2+49 (82%)HR- Her2+11 (18%) Status of Her-2 Positivity IHC positive52 (86%)FISH positive8 (14%) Median tumor size2.6cm (range: 1-8.4cm) Stage Operable (T1-2, N0-1, M0)52 (86%)Operable Stage I7 (12%)Operable Stage II/III45 (74%)Locally advanced (T2-3, N2-3, M0 or T4a-c, any N, M0))7 (12%)Inflammatory (T4d, any N, M0)1 (2%) Type of surgery Lumpectomy30 (50%)Mastectomy30 (50%)
Citation Format: Singh JC, Sugarman S, Jones L, Boafo C, Patil S, Schweber S, Yu A, Argolo D, Modi S, Iyengar N, Smyth L, Norton L, Baselga J, Hudis C, Dang C. Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-17.
Collapse
Affiliation(s)
- JC Singh
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - S Sugarman
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - L Jones
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - C Boafo
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - S Patil
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - S Schweber
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - A Yu
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - D Argolo
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - S Modi
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - N Iyengar
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - L Smyth
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - L Norton
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - C Hudis
- Memorial Sloan Kettering Cancer Center, NY, NY
| | - C Dang
- Memorial Sloan Kettering Cancer Center, NY, NY
| |
Collapse
|
155
|
Argolo D, Friedman M, Smyth L, Iyengar N, Singh J, Patil S, Norton L, Baselga J, Hudis C, Dang C. Abstract P4-13-20: Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Dual anti-HER2 blockade with trastuzumab and pertuzumab (HP) plus chemotherapy is an effective therapy (Rx) in the 1st-line setting for HER2-positive metastatic breast cancer (MBC). Our single arm phase II study included patients (pts) treated with HP plus paclitaxel in the 2nd-line setting with progression-free survival (PFS) benefit. Recently, we reported results from a retrospective study of pts treated at our institution, suggesting a longer PFS for those who received HP-based Rxs when compared to any other anti-HER2 based Rxs in the 2nd-line setting. To further assess the activity of this combination in later Rx lines, we conducted a retrospective analysis of pts with HER2-positive MBC who had progressive disease after 2nd-line and were treated with HP-based Rxs in the 3rd and later lines at MSKCC. Historically, the median (med) PFS in this setting with trastuzumab-based Rx is about 3-4 months.
Methods: Pts diagnosed with HER2-positive MBC and treated with HP-based Rxs at MSKCC between 1-1-2011 and 03-30-2015 and who progressed on 2nd-line Rx were identified through an institutional database. Primary endpoint was PFS in 3rd and later treatment lines.
Results: 70 pts who received any HP-based Rx in the 3rd or later lines of treatment were eligible. The med number of prior anti-HER2 Rx was 3. The baseline characteristics and Rxs are summarized in Table 1. The med PFS for the entire cohort was 5.7 months (95% CI, 4.8-6.5).
Conclusions: In this retrospective analysis involving heavly pretreated patients, HP-based Rx appears to be an active regimen and compares favorably to historical data. This supports the NCCN endorsement of HP-based Rx in later lines if HP has not been delivered previously.
Baseline Characteristics and treatments (n=70)Characteristic(n)(%)Age Median56 Range27-83 Gender Female70100.0Male00.0Race Black1014.3White5477.1Other68.6Ethnicity Non Hispanic6694.3Hispanic45.7ER/PR status ER and PR negative2738.6ER and/or PR positive4361.4Type of disease Non visceral1622.9Visceral5477.1Visceral CNS2130.0Anti-HER2 in early stage Yes2941.4No4158.6Line of therapy 3rd line1927.14th line1521.45th line912.96th line912.97th line811.48th line and beyond1014.3HP-based regimens Chemotherapy + HP5477.1Endocrine therapy + HP57.1HP alone912.9Other22.9
Citation Format: Argolo D, Friedman M, Smyth L, Iyengar N, Singh J, Patil S, Norton L, Baselga J, Hudis C, Dang C. Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-20.
Collapse
Affiliation(s)
- D Argolo
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - M Friedman
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - L Smyth
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - N Iyengar
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - J Singh
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - S Patil
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - L Norton
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - J Baselga
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - C Hudis
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| | - C Dang
- Memorial Sloan Kettering Cancer Center, NY, NY; CLION - CAM Group, Salvador, Bahia, Brazil
| |
Collapse
|
156
|
Ghosh M, ML S, Upasana M, Chodhury S, Mannan AU, Southekal S, Manjima C, Patil S, Murugan K, Mahesh B, Nayak R, Sridhar PSS, Rao N, Krishnamoorthy N, Gupta V, Satheesh CT, Subramanian K, Ajaikumar BS. Abstract P6-06-06: Comprehensive analysis of BRCA (BRCAm) and other germline mutations (GRm) with a clinicopathological association in breast cancer: An Indian study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-06-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BRCAm and other GRm testing using next generation sequencing (NGS) in early diagnosed and/or metastatic breast cancer (BC) helps in the identification of both unambiguously defined deleterious mutations and sequence variants of unknown clinical significance (VUS). The early detection of these mutations in the proband and the family members help in risk stratification and instituting effective monitoring, surveillance and disease management strategies.
Methods: Out of total 200 patients diagnosed with BC (April 2013-15) 77 unrelated individuals were consented to be profiled by NGS on MiSeq platform using TruSight Cancer panel (consisting of 94 genes including 13 genes highly associated with risk of inherited breast and/or ovarian cancer) in an IRB-approved prospective study in a CLIA compliant laboratory. Paired end sequencing was done with an average coverage of > 450X. Data was processed using STRAND software and interpreted using "Strand Omics" platform. The paired tumor samples were analysed for pathological stage, histological type and hormonal status.
Results: GRm were detected in 61 cases (79%). Among all mutations detected, BRCA1/2 were found in 51% (31% in BRCA1, 20% in BRCA2) of cases. BRCA1 was found to be co-mutated with BRCA2 in 2 cases. Out of 37 deleterious mutations in BRCA1/2 genes only 10 were reported to be pathogenic (6 in BRCA1 and 4 in BRCA2) and rest were VUS. Mutation frequencies were higher among high grade IDC with HER2-ve tumors including TNBC (53%, p<0.05) with an early onset of the disease. TNBC with BRCAm were found to have no/incomplete pCR on conventional TAC regimen , subsequently started with platinum therapy and the outcome being monitored. Interestingly, 4 BRCA1 mutations including 3 non-sense and 1 frameshift mutation were found in two unrelated individuals suggesting them to be founder mutations in Indian population. The other GRm frequency (alone/ co-mutated with BRCA) was also found to be significantly high (49%) and include BRIP1, CHEK2, ERCC2, CDH1, SDHB, APC, MSH6, TP53, PALB2 and RAD51C. Stratification based on age of diagnosis(dx) showed a detection rate significantly higher in the age group of 25-50 yrs (74%) as compared to the 50-75 yrs (26%). Also a strong association of GRm status with the family history(Hx) of BC in 1st or 2nd degree relatives was indicated.
Table 1: Correlation of GRm with Dx and HxGenen%Age at dx(yrs)Family Hx (Yes=Y, No=N,Unknown=UK)BRCA1193125-50 (n=23) 50-75(n=8)Y(n=13) N(n=3) UK(n=3)BRCA2122025-50(n=21) 50-75(n=9)Y(n=8) N(n=2) UK(n=2)PALB211.7>50YCHEK258.825-50 (n=4) 50-75(n=1)YATM610.525-50 (n=4) 50-75(n=2)Y(n=5) N(n=1)RAD5111.7<50Y
Conclusions: Our study in a small cohort clearly highlighted the significance of germline testing and classifying the variant in larger cohort of BC patients with a strong family Hx of cancer particularly in BRCA1/2 positive families , and in women <50yrs for early detection and risk assessment. The study also indicates BRCAm to be an important contributor to the etiology of high grade HER2-/ TNBC in Indian patients. Expanded testing of this subtype is warranted to impact management of the disease with PARP inhibitors and/or platinum therapy.
Citation Format: Ghosh M, ML S, Upasana M, Chodhury S, Mannan AU, Southekal S, Manjima C, Patil S, Murugan K, Mahesh B, Nayak R, Sridhar PSS, Rao N, Krishnamoorthy N, Gupta V, Satheesh CT, Subramanian K, Ajaikumar BS. Comprehensive analysis of BRCA (BRCAm) and other germline mutations (GRm) with a clinicopathological association in breast cancer: An Indian study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-06-06.
Collapse
Affiliation(s)
- M Ghosh
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - S ML
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - M Upasana
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - S Chodhury
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - AU Mannan
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - S Southekal
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - C Manjima
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - S Patil
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - K Murugan
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - B Mahesh
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - R Nayak
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - PSS Sridhar
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - N Rao
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - N Krishnamoorthy
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - V Gupta
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - CT Satheesh
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - K Subramanian
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| | - BS Ajaikumar
- Triesta Sciences , Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Health Care Global Enterprises Ltd., Bangalore, Karnataka, India; Strand Center for Genomics and Personalized Medicine, Bangalore, Karnataka, India
| |
Collapse
|
157
|
McArthur HL, Page D, Proverbs-Singh T, Solomon S, Hudis C, Norton L, Patil S, Barrett JA, Lebel F. Abstract OT1-01-05: Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot1-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Immune-based strategies involving T-cell activation have recently shown significant activity in multiple tumor types. The presence of immune elements in breast cancers has prognostic and predictive impact. Thus, strategies that optimize the interplay between a breast cancer and the effected individual's immune system may be therapeutic. Interleukin-12 (IL-12), a pro-inflammatory cytokine, reverses immune escape mechanisms induced by myeloid derived suppressor and dendritic cells which, in turn, improves the function of activated CD8+ T cells and promotes tumor stroma collapse. Because tumor neoantigens may be generated in response to chemotherapy, IL12-mediated immune modulation may be optimal in patients with chemotherapy-sensitive metastatic breast cancer. Ad-RTS-hIL-12 (Ad) is a novel gene therapy candidate expressing IL-12 under the control of an orally-administered activator ligand, veledimex (V) through the proprietary RheoSwitch Therapeutic System® (RTS).
Trial Design: Open-label, phase 1b/2, single-arm, single-center study of Ad+V in women with stable or responsive disease after ≥ 12-weeks of 1st or 2nd-line chemotherapy. Eligible patients will be placed on chemotherapy-holiday and enter the immunotherapy phase, consisting of a single cycle of Ad administered intratumorally (Day 1), along with V (80 mg QDx7). HER2-directed antibody therapy may be continued during the immunotherapy phase for women with HER2- disease.
Key Eligibility Criteria: Women ≥18 years with histologically-confirmed locally advanced or metastatic breast cancer of any subtype who have achieved a partial response (PR) or stable disease (SD) to 1st or 2nd-line chemotherapy are eligible. Exclusion criteria include use of immunosuppressive drugs, compromised immune function, autoimmune disorder, or brain metastases.
Specific Aims: To evaluate the safety and tolerability of Ad+V immunotherapy in eligible women. Secondary endpoints include 12 week overall response rate, 12 week disease control rate and the impact of treatment on exploratory immune biomarkers.
Statistical Methods: Safety and efficacy will be evaluated separately for HER2-/HER2+ patients. Tumor response will be evaluated by RECIST v1.1 at 6 and 12 weeks. To ensure safety, stopping rules defined by grade 3/4 adverse events and12-week progression rate were adopted.
Target Accrual: Up to 40 patients, including up to 8 patients (20%) with HER2+ disease.
Summary: Ad+V is a novel gene therapy which controls local expression of IL-12 and may induce tumor stroma collapse and stimulation of an anti-cancer T cell immune response. The ability to regulate the production of IL-12 by modulating V dosing may result in an improved therapeutic index in combination with standard of care. The data from this study will directly inform future studies.
Study Contact (Clinical Trials.gov: NCT02423902).
Citation Format: McArthur HL, Page D, Proverbs-Singh T, Solomon S, Hudis C, Norton L, Patil S, Barrett JA, Lebel F. Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT1-01-05.
Collapse
Affiliation(s)
- HL McArthur
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - D Page
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - T Proverbs-Singh
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - S Solomon
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - C Hudis
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - L Norton
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - S Patil
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - JA Barrett
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| | - F Lebel
- Memorial Sloan Kettering Cancer Center, NY, NY; ZIOPHARM Oncology, Inc., Boston, MA
| |
Collapse
|
158
|
Morikawa A, De Stanchina E, Patil S, Chandarlapaty S, Li BT, Norton L, Seidman AD. Abstract P4-14-24: Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-24] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Systemic treatment of central nervous system (CNS) metastases remains a challenge partially due to poor drug penetration. Lapatinib and capecitabine are drugs with modest efficacy in treatment of brain metastases from HER2-positive (+) breast cancer (BC) and were shown to cross the blood-tumor barrier in clinical craniotomy specimens (Lin N et al., CCR 2009, Morikawa A et al., Neuro Oncol 2015). However, intratumoral drug concentrations observed were sub-optimal and heterogeneous. Administration of shorter-duration, high dose tyrosine kinase inhibitor is proposed as a way to improve efficacy and tolerability based on Norton-Simon modeling and drug exposure in the CNS (Traina T et al., JCO 2008, Grommes C et al., Neuro Oncol 2011, Chien AJ et al., J Clin Oncol 2014) . In this study, we examined optimization of high dose lapatinib administration with or without capecitabine to inform the design of a phase I trial for BC patients with HER2+ CNS metastases.
Methods: Mice bearing BT-474 BC xenograft tumors were treated with various lapatinib doses and schedules. A standard continuous daily dose (100mg/kg) was compared to various intermittent dosing schedules (at 100mg/kg, 400mg/kg, and 800mg/kg). In addition, high dose lapatinib (800mg/kg) was administered with capecitabine either concurrently or in tandem. Xenografts were treated when tumors reached 100mm3. Tumor volumes were evaluated for antitumor efficacy, and mice weights were measured for toxicity. Significance testing for between-group comparisons was conducted using a mixed effect model for repeated measures.
Results: Intermittent schedules of lapatinib at 100mg/kg given as 3 days on/11 days off (3/11), 5 days on/9 days off (5/9), and 7 days on/7days off (7/7) had a similar efficacy in tumor control: percent change in tumor volume of 225% (7/7), 222% (5/9), and 223% (3/11) (NS). Therefore, the 3 days on (with 4 days off or 11 days off ) schedule was subsequently chosen to evaluate for tolerability and antitumor efficacy of higher lapatinib dose. The 3 days on/4 days off (3/4) group at 800mg/kg demonstrated the highest tumor reduction (-69%) compared to the daily continuous dosing group (-18%) (p=0.04), but a trend toward higher toxicity was observed (p=0.12). Evaluation of concurrent vs. tandem administration of capecitabine with lapatinib at 800mg/kg given in 3 days on/11 days off was conducted. The concurrent treatment was discontinued early due to high toxicity. However, tandem administration of capecitabine with high dose lapatinib was tolerable without a significant difference in weight changes (p=0.62).
Conclusions: The intermittent schedule allows delivery of high dose lapatinib, which has better anti-tumor activity than standard continuous dosing. If given intermittently, high dose lapatinib is tolerable, even with capecitabine if given in tandem/sequence. Based on the result of these experiments, a phase I trial of high dose lapatinib using 3 days on/11 days off schedule in tandem with capecitabine is currently proposed for treatment of HER2-positive BC patient with CNS metastases.
Citation Format: Morikawa A, De Stanchina E, Patil S, Chandarlapaty S, Li BT, Norton L, Seidman AD. Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-24.
Collapse
Affiliation(s)
- A Morikawa
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, NY, NY
| | - E De Stanchina
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, NY, NY
| | - S Patil
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, NY, NY
| | - S Chandarlapaty
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, NY, NY
| | - BT Li
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, NY, NY
| | - L Norton
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, NY, NY
| | - AD Seidman
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, NY, NY
| |
Collapse
|
159
|
|
160
|
Sharma R, Dhingra N, Patil S. CoMFA, CoMSIA, HQSAR and molecular docking analysis of ionone-based chalcone derivatives as antiprostate cancer activity. Indian J Pharm Sci 2016; 78:54-64. [DOI: 10.4103/0250-474x.180251] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
161
|
Sharma R, Dhingra N, Patil S. CoMFA, CoMSIA, HQSAR and Molecular Docking Analysis of Ionone-based Chalcone Derivatives as Antiprostate Cancer Activity. Indian J Pharm Sci 2016. [PMID: 27168682 PMCID: PMC4852576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Androgen receptor has been proved to be effective site for treatment of prostate cancer. Molecular modeling methods performed on forty-three ionone based chalcones derivatives as anti-prostate cancer activity. The designed comparative molecular field analysis, comparative similarity indices analysis and hologram quantitative structure activity relationship models produced statistically significant results with the cross-validated correlation coefficients (q2) of 0.527, 0.550 and 0.670, non-cross-validated correlation coefficients (r2) 0.636, 0.671 and 0.746 and predicted r2 (Pred r2) of 0.621, 0.563 and 0.732, respectively. Furthermore, bioactive conformation was explored and explained by docking of the potent compound 25 into the binding site of androgen receptor. Present study deals with comparative molecular field analysis, comparative similarity indices analysis and hologram quantitative structure activity relationship and molecular docking studies of the ionone-based chalcones and their derivatives, obtained from literature. The model obtained could be effectively used as a channeling tool for further structure modification and designing of some novel potent anti-prostate cancer compounds.
Collapse
Affiliation(s)
- R. Sharma
- School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshashila Campus, Indore-452 001, India,Address for correspondence: E-mail:
| | - N. Dhingra
- School of Life Sciences, Devi Ahilya Vishwavidyalaya, Takshashila Campus, Indore-452 001, India
| | - S. Patil
- School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshashila Campus, Indore-452 001, India
| |
Collapse
|
162
|
Natesh BG, Patil S, Nilssen E, Maclean H. Endonasal Microdebrider Assisted Excision of Congenital Intranasal Nasolacrimal Duct Cyst or Inferior Mucocoele. Indian J Otolaryngol Head Neck Surg 2015; 68:115-7. [PMID: 27066426 DOI: 10.1007/s12070-015-0948-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 12/10/2015] [Indexed: 11/27/2022] Open
Abstract
OBJECTIVE Congenital intranasal nasolacrimal duct (NLD) cyst is a rare clinical entity in the newborn whilst inferior mucocoeles are more common. We reviewed our case series of the management of patients presenting with congenital intranasal NLD cysts and inferior mucocoeles treated using powered instrumentation under endoscopic guidance. METHODS A retrospective review identified three patients, between 2010 and 2013, who have had microdebrider assisted endoscopic marsupialisation of congenital intranasal NLD cysts under joint ENT and Ophthalmology care. RESULTS Diagnosis was made based on intraoperative endoscopic nasal examination carried out during treatment of patients with epiphora. All patients were 2 years old or younger presented with persistent epiphora since birth with sticky eyes. All had normal development with no other past medical history of note. Two patients had unilateral and one patient had bilateral congenital intranasal NLD cysts/inferior mucocoels identified. These were treated by endoscopic incision of the cyst with drainage of pus and excision of excess mucosal tissue using a powered microdebrider to effect marsupialisation and prevent re healing of the floppy redundant flaps of the incised cyst. No silastic tubes were placed. All patients were discharged from clinic 3 months post surgery with complete resolution of symptoms and no complications. CONCLUSIONS Microdebrider assisted endoscopic marsupialisation is a safe and effective treatment for removal of excess tissue in the treatment for congenital intranasal NLD cyst/inferior mucocoele whilst also obviating the need for silastic intubation and a further general anaesthetic for stent removal.
Collapse
Affiliation(s)
- B G Natesh
- Queen Alexandra Hospital, Portsmouth, UK
| | - S Patil
- Royal Surrey County Hospital, Guilford, UK
| | - E Nilssen
- Queen Alexandra Hospital, Portsmouth, UK
| | - H Maclean
- Queen Alexandra Hospital, Portsmouth, UK
| |
Collapse
|
163
|
Patil S, Rege G, Anand L, Iyer V, Dash P. Clinical and hemodynamic profiles of different etiologies of severe aortic stenosis. Indian Heart J 2015. [DOI: 10.1016/j.ihj.2015.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
164
|
Maag JLV, Panja D, Sporild I, Patil S, Kaczorowski DC, Bramham CR, Dinger ME, Wibrand K. Dynamic expression of long noncoding RNAs and repeat elements in synaptic plasticity. Front Neurosci 2015; 9:351. [PMID: 26483626 PMCID: PMC4589673 DOI: 10.3389/fnins.2015.00351] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 09/16/2015] [Indexed: 01/29/2023] Open
Abstract
Long-term potentiation (LTP) of synaptic transmission is recognized as a cellular mechanism for learning and memory storage. Although de novo gene transcription is known to be required in the formation of stable LTP, the molecular mechanisms underlying synaptic plasticity remain elusive. Noncoding RNAs have emerged as major regulatory molecules that are abundantly and specifically expressed in the mammalian brain. By combining RNA-seq analysis with LTP induction in the dentate gyrus of live rats, we provide the first global transcriptomic analysis of synaptic plasticity in the adult brain. Expression profiles of mRNAs and long noncoding RNAs (lncRNAs) were obtained at 30 min, 2 and 5 h after high-frequency stimulation of the perforant pathway. The temporal analysis revealed dynamic expression profiles of lncRNAs with many positively, and highly, correlated to protein-coding genes with known roles in synaptic plasticity, suggesting their possible involvement in LTP. In light of observations suggesting a role for retrotransposons in brain function, we examined the expression of various classes of repeat elements. Our analysis identifies dynamic regulation of LINE1 and SINE retrotransposons, and extensive regulation of tRNA. These experiments reveal a hitherto unknown complexity of gene expression in long-term synaptic plasticity involving the dynamic regulation of lncRNAs and repeat elements. These findings provide a broader foundation for elucidating the transcriptional and epigenetic regulation of synaptic plasticity in both the healthy brain and in neurodegenerative and neuropsychiatric disorders.
Collapse
Affiliation(s)
- Jesper L V Maag
- Genomics and Epigenetics Division, Garvan Institute of Medical Research Sydney, NSW, Australia ; Faculty of Medicine, St Vincent's Clinical School, University of New South Wales Sydney, NSW, Australia
| | - Debabrata Panja
- Department of Biomedicine and K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen Bergen, Norway
| | - Ida Sporild
- Department of Biomedicine and K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen Bergen, Norway
| | - Sudarshan Patil
- Department of Biomedicine and K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen Bergen, Norway
| | - Dominik C Kaczorowski
- Genomics and Epigenetics Division, Garvan Institute of Medical Research Sydney, NSW, Australia
| | - Clive R Bramham
- Department of Biomedicine and K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen Bergen, Norway
| | - Marcel E Dinger
- Genomics and Epigenetics Division, Garvan Institute of Medical Research Sydney, NSW, Australia ; Faculty of Medicine, St Vincent's Clinical School, University of New South Wales Sydney, NSW, Australia
| | - Karin Wibrand
- Department of Biomedicine and K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Bergen Bergen, Norway
| |
Collapse
|
165
|
Nasrallah L, Jennings J, Cummings D, Russo D, Rodebaugh L, Feldhousen E, Nye A, Hardee J, Patil S. Teleteam Care for Diabetes: Promoting Lifestyle and Behavioral Health for Uncontrolled Diabetic Patients in Underserved Rural Communities via Telehealth. J Acad Nutr Diet 2015. [DOI: 10.1016/j.jand.2015.06.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
166
|
Bortz H, Coutsouvelis J, Corallo CE, Spencer A, Patil S. Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease. J Clin Pharm Ther 2015; 40:483-5. [PMID: 26073601 DOI: 10.1111/jcpt.12293] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2015] [Accepted: 05/07/2015] [Indexed: 11/28/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Intensive chemotherapy for treatment of Burkitt's lymphoma (BL) - a high-grade lymphoproliferative disorder (LPD) - can cause neurotoxicity. An association between motor neurone disease (MND) and LPDs has previously been described, but there is a lack of recommendations available to guide management of such patients. This report aims to describe suitable management of BL in a patient with MND. CASE DESCRIPTION A 66-year-old woman with a history of MND affecting her limbs was diagnosed with bulky, extranodal, high-risk gastric BL. Standard chemotherapy is with multiple non-cross-resistant cytotoxic agents. To avoid exacerbation of neuropathy, six cycles of a modified regimen was planned, aiming to minimize exposure to the most neurotoxic agents. A PET-FDG-negative remission was obtained at 12 months, without the signs of central neurotoxicity, peripheral neuropathy or muscle weakness. WHAT IS NEW AND CONCLUSION High-intensity chemotherapy, minimizing known neurotoxic agents, was delivered safely and effectively in a patient with BL and pre-existing MND. More case descriptions are required to guide management decisions.
Collapse
Affiliation(s)
- H Bortz
- Pharmacy Department, Alfred Health, The Alfred Hospital, Melbourne, Vic., Australia
| | - J Coutsouvelis
- Pharmacy Department, Alfred Health, The Alfred Hospital, Melbourne, Vic., Australia.,Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, The Alfred Hospital, Melbourne, Vic., Australia
| | - C E Corallo
- Pharmacy Department, Alfred Health, The Alfred Hospital, Melbourne, Vic., Australia
| | - A Spencer
- Department of Malignant Haematology and Stem Cell Transplantation, The Alfred Hospital, Melbourne, Vic., Australia
| | - S Patil
- Department of Malignant Haematology and Stem Cell Transplantation, The Alfred Hospital, Melbourne, Vic., Australia
| |
Collapse
|
167
|
Hashimoto A, Nakata T, Moroi M, Tamaki N, Nishimura T, Hasebe N, Kikuchi K, Salgado C, Jimenez-Heffernan A, Lopez-Martin J, Ramos-Font C, Sanchez De Mora E, Rivera F, Lopez-Aguilar R, Martinez A, Manovel A, Soriano E, Mushtaq S, Pontone G, Bertella E, Conte E, Segurini C, Volpato V, Beltrama V, Pepi M, Annoni A, Andreini D, Leen A, Scholte A, De Graaf M, Van Den Hoogen I, Kharagjitsingh A, Wolterbeek R, Kroft L, Jukema J, Bax J, Piccinelli M, Santana C, Sirineni G, Cooke C, Aguade Bruix S, Keidar Z, Frenkel A, Israel O, Candell Riera J, Garcia E, Sharma A, Bajwa A, Bhatnagar U, Thompson E, Patil S, Thompson R, Khoorshed A, Spencer F, Farncombe T, Tandon V, Singnurkar A, Gulenchyn K, Benito Gonzalez TF, Delgado Sanchez-Gracian C, Trinidad Lopez C, Mera Fernandez D, Villanueva Campos AM, Bustos Fiore A, Alonso Fernandez V, Mayorga Bajo A, Martinez Paz E, Iglesias Garriz I. Moderated Poster Session 1: Sunday 3 May 2015, 10:00-11:00 * Room: Moderated Poster Area. Eur Heart J Cardiovasc Imaging 2015. [DOI: 10.1093/ehjci/jev045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
168
|
Abstract
BACKGROUND Dental treatment can be highly unpleasant for anxious patients. Despite all advancements, dental anxiety continues to upset the dentist-patient relationship. The psychological factors like individual personality and familial and peer influence may alter the dental beliefs of a patient. AIM A cross-sectional questionnaire study was conducted among young adolescents to investigate the relationship among various psychological factors and the dental beliefs of an individual. MATERIALS AND METHODS A self-administered questionnaire was distributed among higher secondary school children, aged 15-17 years in Udupi district. The dental anxiety of the participants was measured using Modified Dental Beliefs scale and the personality traits were assessed using the Ten-Item Personality Inventory. Pearson's correlation and chi-square analysis were performed among these scales. Independent t-test was performed to compare dental anxiety scores with different socio-demographic and psychological characteristics. RESULTS In all 198 students, with a mean age of 16.6 years, completed the questionnaire. A majority of the participants had lower MDBS scores. The personality traits like Emotional Stability and Openness to New Experiences showed a negative correlation with the Dental Belief scores. Apart from these, the experience at first dental visit and peer support also affected the dental beliefs of the adolescents. CONCLUSION Various psychological traits of adolescents influence their dental anxiety.
Collapse
Affiliation(s)
- Siddhi Hathiwala
- Department of Public Health Dentistry, Rungta College of Dental Sciences and Research, Bhilai, Chhattisgarh, India
| | | | | |
Collapse
|
169
|
Di Filippo G, Trioni MI, Fratesi G, Schumann FO, Wei Z, Li CH, Behnke L, Patil S, Kirschner J, Stefani G. The LVV Auger line shape of sulfur on copper studied by Auger photoelectron coincidence spectroscopy. J Phys Condens Matter 2015; 27:085003. [PMID: 25650803 DOI: 10.1088/0953-8984/27/8/085003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We have studied the line shapes of Cu(0 0 1)-p (2 × 2)S L2VV and L3VV Auger decay by means of Auger photoelectron coincidence spectroscopy. Measuring the LVV Auger spectrum in coincidence with S 2p1/2 and 2p3/2 photoelectrons respectively, we have been able to separate the two overlapping Auger spectra and determine their intrinsic line shapes. The two Auger transitions, though shifted in energy, display an identical line shape whose main features can be qualitatively understood considering a single particle approximation but are better described within a Cini-Sawatzky (CS) approach. Comparison between the experimental and the CS calculated spectra confirms that a substantial part of the Auger lines (∼20%) can be ascribed to decay events accompanied by the excitation of one additional electron-hole pair in the valence band. For the first time, the locality of the Auger process combined with the surface sensitivity of the APECS technique and its ability to separate overlapping structures are used to study Auger transitions taking place at the the surface states of a S/noble-metal interface.
Collapse
Affiliation(s)
- G Di Filippo
- Scuola dottorale in Matematica e Fisica, Università di Roma Tre, via della Vasca Navale 84, I-00146 Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
170
|
Shwetha S, Patil S, Ram D. Paranormal Believe and Medication Adherence in Patient with Depression. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)31014-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
171
|
Patil S, Davies P. [Going to Babylon with Google]. MMW Fortschr Med 2015; 157:35. [PMID: 25743662 DOI: 10.1007/s15006-015-2694-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|
172
|
Page D, Yuan J, Dong Z, Ginsberg A, Wong P, Emerson R, Sung J, Comstock C, Mu Z, Solomon S, Diab A, Durack J, Maybody M, Erinjeri J, Brogi E, Morris E, Patil S, Robins H, Wolchok J, Hudis C, Norton L, Allison J, McArthur H. FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.12.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
173
|
Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, Desai S, Dutt S, Veldore V, Jambhekar N, Mehta A, Hazarika D, Azam S, Gawande S, Gupta S. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther 2015; 8:117-23. [PMID: 25609979 PMCID: PMC4293920 DOI: 10.2147/ott.s74820] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Background Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a common feature observed in lung adenocarcinoma. A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the intracellular domain of anaplastic lymphoma kinase (ALK), named EML4-ALK, has been identified in a subset of non-small-cell lung cancer (NSCLC) tumors. The objective of this study was to determine the prevalence of EGFR mutations and EML4-ALK fusions in Indian patients with NSCLC (adenocarcinoma) as well as evaluate their clinical characteristics. Patients and methods Patients with NSCLC, adenocarcinoma histology, whose tumors had been tested for EGFR mutational status, were considered for this study. ALK gene rearrangement was detected by fluorescence in situ hybridization using the Vysis ALK Break Apart Rearrangement Probe Kit. ALK mutation was tested in samples that were negative for EGFR mutation. Results A total of 500 NSCLC adenocarcinoma patients were enrolled across six centers. There were 337 (67.4%) men and 163 (32.6%) women with a median age of 58 years. One hundred and sixty-four (32.8%) blocks were positive for EGFR mutations, whereas 336 (67.2%) were EGFR wild-type. Of the 336 EGFR-negative blocks, EML4-ALK fusion gene was present in 15 (4.5%) patients, whereas 321 (95.5%) tumors were EML4-ALK negative. The overall incidence of EML4-ALK fusion gene was 3% (15/500). Conclusion The incidence of EGFR mutations (33%) in this Indian population is close to the reported incidence in Asian patients. EML4-ALK gene fusions are present in lung adenocarcinomas from Indian patients, and the 3% incidence of EML4-ALK gene fusion in EGFR mutation-negative cases is similar to what has been observed in other Western and Asian populations. The mutual exclusivity of EML4-ALK and EGFR mutations suggests implementation of biomarker testing for tumors harboring ALK rearrangements in order to identify patients that can benefit from newer targeted therapies.
Collapse
Affiliation(s)
- Dc Doval
- Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | | | - S Patil
- Bangalore Institute of Oncology, HCG Group, Bengaluru, India
| | | | - C Goswami
- B. P. Poddar Hospital, Kolkata, India
| | - Ak Vaid
- Medanta The Medicity, Gurgaon, India
| | - S Desai
- Tata Memorial Hospital, Mumbai, India
| | - S Dutt
- Oncquest Laboratories Ltd., New Delhi, India
| | - Vh Veldore
- Triesta Reference Laboratory, HCG Group, Bengaluru, India
| | | | - A Mehta
- Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | - D Hazarika
- Triesta Reference Laboratory, HCG Group, Bengaluru, India
| | - S Azam
- Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
| | | | - S Gupta
- Catalyst Clinical Services Pvt. Ltd., New Delhi, India
| |
Collapse
|
174
|
Patil S, Thippeswamy R, Shashidara HP, Satheesh CT, Vittal H, Mishra S. Eribulin mesylate in Indian patients: A single center experience. Indian J Cancer 2015; 52:297-8. [DOI: 10.4103/0019-509x.176735] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
175
|
Sharma R, Patil S, Abhishek A. Comparative study to predict dipeptidyl peptidase IV inhibitory activity of β-amino amide scaffold. Indian J Pharm Sci 2015; 77:142-50. [PMID: 26009645 PMCID: PMC4442461 DOI: 10.4103/0250-474x.156545] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2013] [Revised: 10/28/2014] [Accepted: 03/02/2015] [Indexed: 11/18/2022] Open
Abstract
Comparative study was performed on 34 β-amino amide derivatives as dipeptidyl peptidase IV inhibitors in order to determine their structural requirement to enhance the antidiabetic activities. Hologram quantitative structure activity relationships models utilized specialized fragment fingerprints (hologram length 353) which showed good predictivity with cross-validated q2 and conventional r2 values of 0.971 and 0.971, respectively. Models were validated and optimized by a test set of eight compounds and gave satisfactory predictive ability. Hologram quantitative structure activity relationships maps were helpful in prediction of the structural features of the ligands to account for the activity in terms of positively and negatively contributing towards activity. The information obtained from maps could be effectively use as a guiding tool for further structure modifications and synthesis of new potent antidiabetic agents.
Collapse
|
176
|
Patil S, Zaky W, Park M, Liu D, Khatua S. ED-24 * GANGLIOGLIOMAS IN CHILDREN- THE MD ANDERSON CANCER CENTER EXPERIENCE. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou253.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
177
|
Dutt S, Advani S, Dhabhar B, Dattatreya P, Patil S, Chatterjee S, Srinivasan S, Mishra D, Raja T, Pavithran K, Reddy P, Nambiar R, Gaur R. Experience of Alk Mutation Testing in 3351 Indian Patients of Nsclc. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
178
|
Ziuzina D, Patil S, Cullen P, Keener K, Bourke P. Atmospheric cold plasma inactivation of Escherichia coli, Salmonella enterica serovar Typhimurium and Listeria monocytogenes inoculated on fresh produce. Food Microbiol 2014; 42:109-16. [DOI: 10.1016/j.fm.2014.02.007] [Citation(s) in RCA: 226] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Revised: 01/13/2014] [Accepted: 02/11/2014] [Indexed: 10/25/2022]
|
179
|
Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, Desai S, Dutt S, Veldore V, Jambhekar N, Mehta A, Hazarika D, Azam S, Gupta S, Gawande S. Demographic and Epidemiological Characteristic of Egfr Mutation and Alk Gene Rearrangement Among Indian Patients with Lung Adenocarcinoma. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
180
|
Peirs C, Patil S, Bouali-Benazzouz R, Artola A, Landry M, Dallel R. Protein kinase C gamma interneurons in the rat medullary dorsal horn: distribution and synaptic inputs to these neurons, and subcellular localization of the enzyme. J Comp Neurol 2014; 522:393-413. [PMID: 23818225 DOI: 10.1002/cne.23407] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2012] [Revised: 06/21/2013] [Accepted: 06/21/2013] [Indexed: 12/18/2022]
Abstract
The γ isoform of protein kinase C (PKCγ), which is concentrated in interneurons in the inner part of lamina II (IIi ) of the dorsal horn, has been implicated in the expression of tactile allodynia. Lamina IIi PKCγ interneurons were shown to be activated by tactile inputs and to participate in local circuits through which these inputs can reach lamina I, nociceptive output neurons. That such local circuits are gated by glycinergic inhibition and that A- and C-fibers low threshold mechanoreceptors (LTMRs) terminate in lamina IIi raise the general issue of synaptic inputs to lamina IIi PKCγ interneurons. Combining light and electron microscopic immunochemistry in the rat spinal trigeminal nucleus, we show that PKCγ-immunoreactivity is mostly restricted to interneurons in lamina IIi of the medullary dorsal horn, where they constitute 1/3 of total neurons. The majority of synapses on PKCγ-immunoreactive interneurons are asymmetric (likely excitatory). PKCγ-immunoreactive interneurons appear to receive exclusively myelinated primary afferents in type II synaptic glomeruli. Neither large dense core vesicle terminals nor type I synaptic glomeruli, assumed to be the endings of unmyelinated nociceptive terminals, were found on these interneurons. Moreover, there is no vesicular glutamate transporter 3-immunoreactive bouton, specific to C-LTMRs, on PKCγ-immunoreactive interneurons. PKCγ-immunoreactive interneurons contain GABAA ergic and glycinergic receptors. At the subcellular level, PKCγ-immunoreactivity is mostly concentrated on plasma membranes, close to, but not within, postsynaptic densities. That only myelinated primary afferents were found to contact PKCγ-immunoreactive interneurons suggests that myelinated, but not unmyelinated, LTMRs play a critical role in the expression of mechanical allodynia.
Collapse
Affiliation(s)
- Cédric Peirs
- Inserm/UdA U1107, Neuro-Dol: Trigeminal Pain and Migraine, Université d'Auvergne, Faculté de Chirurgie Dentaire, Clermont-Ferrand, 63000, France
| | | | | | | | | | | |
Collapse
|
181
|
Fedele PL, Avery S, Patil S, Spencer A, Haas M, Wei A. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia. Intern Med J 2014; 44:757-63. [DOI: 10.1111/imj.12478] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Accepted: 05/12/2014] [Indexed: 11/29/2022]
Affiliation(s)
- P. L. Fedele
- Department of Clinical Haematology; The Alfred Hospital; Melbourne Victoria Australia
| | - S. Avery
- Department of Clinical Haematology; The Alfred Hospital; Melbourne Victoria Australia
| | - S. Patil
- Department of Clinical Haematology; The Alfred Hospital; Melbourne Victoria Australia
| | - A. Spencer
- Department of Clinical Haematology; The Alfred Hospital; Melbourne Victoria Australia
| | - M. Haas
- Centre for Health Economics Research and Evaluation; University of Technology; Sydney New South Wales Australia
| | - A. Wei
- Department of Clinical Haematology; The Alfred Hospital; Melbourne Victoria Australia
- Australian Centre for Blood Diseases; Monash University; Melbourne Victoria Australia
| |
Collapse
|
182
|
Patil SB, Hugar S, Patil S. Green teeth associated with hyperbilirubinemia: a case report. Eur J Paediatr Dent 2014; 15:221-223. [PMID: 25101508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Green stain is an uncommon clinical condition associated with deposition of bilirubin in the dental hard tissues. The staining of the teeth is due to hyperbilirubinemia caused by systemic conditions. CASE REPORT The purpose of this report is to present a case of green teeth of the primary dentition in a 17-month old girl associated with hydrocephalus and Hirschprung's disease. CONCLUSION The clinical characteristics of the teeth may help in the diagnosis of current or past systemic diseases.
Collapse
Affiliation(s)
- S B Patil
- Department of Pedodontics and Preventive Dentistry, Kle Vk Institute of Dental Sciences, Belgaum, India
| | - S Hugar
- Department of Pedodontics and Preventive Dentistry, Kle Vk Institute of Dental Sciences, Belgaum, India
| | - S Patil
- Department of oral pathology, Faculty of Dental Sciences, M S Ramaiah University of applied Sciences, Bangalore, India
| |
Collapse
|
183
|
Panosyan E, Gotesman M, Kallay T, Martinez S, Bolaris M, Lasky J, Fouyssac F, Gentet JC, Frappaz D, Piguet C, Gorde-Grosjean S, Grill J, Schmitt E, Pall-Kondolff S, Chastagner P, Dudley R, Torok M, Gallegos D, Liu A, Handler M, Hankinson T, Dudley R, Torok M, Gallegos D, Liu A, Handler M, Hankinson T, Fukuoka K, Yanagisawa T, Suzuki T, Shirahata M, Adachi JI, Mishima K, Fujimaki T, Matsutani M, Sasaki A, Wada S, Nishikawa R, Suzuki M, Kondo A, Miyajima M, Arai H, Morin S, Uro-Coste E, Munzer C, Gambart M, Puget S, Miquel C, Maurage CA, Dufour C, Leblond P, Andre N, Kanold J, Icher C, Bertozzi AAI, Diez B, Muggeri A, Cerrato S, Calabrese B, Arakaki N, Marron A, Sevlever G, Fisher MJ, Widemann BC, Dombi E, Wolters P, Cantor A, Vinks A, Parentesis J, Ullrich N, Gutmann D, Viskochil D, Tonsgard J, Korf B, Packer R, Weiss B, Fisher MJ, Marcus L, Weiss B, Kim A, Dombi E, Baldwin A, Whitcomb P, Martin S, Gillespie A, Doyle A, Widemann BC, Bulwer C, Gan HW, Ederies A, Korbonits M, Powell M, Jeelani O, Jacques T, Stern E, Spoudeas H, Kimpo M, Tang J, Tan CL, Yeo TT, Chong QT, Ruland V, Hartung S, Kordes U, Wolff JE, Paulus W, Hasselblatt M, Patil S, Zaky W, Khatua S, Lassen-Ramshad Y, Christensen L, Clausen N, Bendel A, Dobyns W, Bennett J, Reyes-Mugica M, Petronio J, Nikiforova M, Mueller H, Kirches E, Korshunov A, Pfister S, Mawrin C, Hemenway M, Foreman N, Kumar A, Kalra S, Acharya R, Radhakrishnan N, Sachdeva A, Nimmervoll B, Hadjadj D, Tong Y, Shelat AA, Low J, Miller G, Stewart CF, Guy RK, Gilbertson RJ, Miwa T, Nonaka Y, Oi S, Sasaki H, Yoshida K, Northup R, Klesse L, McNall-Knapp R, Blagia M, Romeo F, Toscano S, D'Agostino A, Lafay-Cousin L, Lindzon G, Bouffet E, Taylor M, Hader W, Nordal R, Hawkins C, Laperriere N, Laughlin S, Shash H, McDonald P, Wrogemann J, Ahsanuddin A, Matsuda K, Soni R, Vanan MI, Cohen K, Taylor I, Rodriguez F, Burger P, Yeh J, Rao S, Iskandar B, Kienitz BA, Bruce R, Keller L, Salamat S, Puccetti D, Patel N, Hana A, Gunness VRN, Berthold C, Hana A, Bofferding L, Neuhaeuser C, Scalais E, Kieffer I, Feiden W, Graf N, Boecher-Schwarz H, Hertel F, Cruz O, Morales A, de Torres C, Vicente A, Gonzalez MA, Sunol M, Mora J, Garcia G, Guillen A, Muchart J, Yankelevich M, Sood S, Diver J, Savasan S, Poulik J, Bhambhani K, Hochart A, Gaillard V, Bonne NX, Baroncini M, Andre N, Vannier JP, Dubrulle F, Lejeune JP, Vincent C, Leblond P, Japp A, Gessi M, Muehlen AZ, Klein-Hitpass L, Pietsch T, Sharma M, Yadav R, Malgulwar PB, Pathak P, Sigamani E, Suri V, Sarkar C, Jagdevan A, Singh M, Sharma BS, Garg A, Bakhshi S, Faruq M, Doromal D, Villafuerte CJ, Tezcanli E, Yilmaz M, Sengoz M, Peker S, Dhall G, Robison N, Margol A, Evans A, Krieger M, Finlay J, Rosser T, Khakoo Y, Pratilas C, Marghoob A, Berger M, Hollmann T, Rosenblum M, Mrugala M, Giglio P, Keene C, Ferreira M, Garcia D, Weil A, Khatib Z, Diaz A, Niazi T, Bhatia S, Ragheb J, Robison N, Rangan K, Margol A, Rosser T, Finlay J, Dhall G, Gilles F, Morris C, Chen Y, Shetty V, Elbabaa S, Guzman M, Abdel-Baki MS, Abdel-Baki MS, Waguespack S, Jones J, Stapleton S, Baskin D, M, Okcu F. RARE TUMOURS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
184
|
Poddubnaya I, Babicheva L, Kaplanov K, Zaritskey A, Volodicheva E, Alexeev S, Loginov A, Orlova R, Dvornichenko V, Gladkov O, Kosinova M, Serduk O, Milovanov V, Myasnikov A, Suresh AV, Jain M, Patil S, Rajappa SJ, Ivanov R, Chernyaeva E. Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19545] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. Poddubnaya
- Russian Medical Academy for Postgraduate Education, Oncology Department, Moscow, Russia
| | - L. Babicheva
- Russian Medical Academy for Postgraduate Education, Oncology Department, Moscow, Russia
| | - K. Kaplanov
- Volgograd Regional Clinical Oncological Dispensary, Volgograd, Russia
| | - Andrey Zaritskey
- Federal State Budgetary Institution “Federal Center of Heart, Blood and Endocrinology n.a. Almazov” of Ministry of Health of Russia, Saint Petersburg, Russia
| | | | - S. Alexeev
- Petrov Research Institute of Oncology, Saint Petersburg, Russia
| | - A. Loginov
- Haematology Centre at the Central City Hospital # 7, Yekaterinburg, Russia
| | - R. Orlova
- St. Petersburg Municipal Clinical Oncology Dispensary, Saint Petersburg, Russia
| | | | - Oleg Gladkov
- Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russia
| | - M. Kosinova
- Kemerovo Region Regional Clinical Hospital, Kemerovo, Russia
| | - O. Serduk
- Krasnodar Clinical Oncology Dispensary # 1, Krasnodar, Russia
| | - V. Milovanov
- Tambov Regional Clinical Oncology Dispensary, Tambov, Russia
| | - A. Myasnikov
- Republican Hospital named after V.A. Baranov, Petrozavodsk, Russia
| | | | | | - S. Patil
- Bangalore Institute of Oncology, Bangalore, India
| | | | | | | |
Collapse
|
185
|
Subramaniyan S, Heo S, Patil S, Li L, Hoger H, Pollak A, Lubec G. A hippocampal nicotinic acetylcholine alpha 7-containing receptor complex is linked to memory retrieval in the multiple-T-maze in C57BL/6j mice. Behav Brain Res 2014; 270:137-45. [PMID: 24837029 DOI: 10.1016/j.bbr.2014.05.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 05/02/2014] [Accepted: 05/05/2014] [Indexed: 12/13/2022]
Abstract
The link between the cholinergic and serotonergic system in cognitive function is well-documented. There is, however, limited information on spatial memory and this formed the rationale to carry out a study with the aim to show a specific link between nicotinic and serotonergic receptor complexes rather than the corresponding subunits, to spatial memory retrieval in a land maze. A total of 46 mice were used and divided into two groups, trained and untrained (yoked) in the multiple-T-Maze (MTM) and following training during the first four days, probe trials for memory retrieval were performed on days 8, 16 and 30. Six hours following scarification, hippocampi were taken for the analysis of native receptor complex levels using blue-native gels followed by immunoblotting with specific antibodies. 5-HT1A-, 5-HT7-, nAChα4- and nACh-α7-containing receptor complexes were observed and were paralleling memory retrievals and receptor complex levels were shown to be significantly different between trained and yoked animals. Only levels of a nicotinic acetylcholine α7 receptor-containing complex at an apparent molecular weight of approximately 480kDa were shown to be linked to memory retrieval on day 8 but not to retrievals on days 16 and 30 when memory extinction has taken place. Correlation between nAChα4-, 5-HT1A- and 5-HT7-containing receptors and latencies on day 16 may point to a probable link in extinction mechanisms. A series of the abovementioned receptor complexes were correlating among each other probably indicating a serotonergic/cholinergic network paralleling spatial memory formation.
Collapse
Affiliation(s)
- Saraswathi Subramaniyan
- Department of Pediatrics, Medical University of Vienna, Austria Währinger Gürtel 18, A 1090 Vienna, Austria
| | - Seok Heo
- Department of Pediatrics, Medical University of Vienna, Austria Währinger Gürtel 18, A 1090 Vienna, Austria
| | - Sudarshan Patil
- Department of Pediatrics, Medical University of Vienna, Austria Währinger Gürtel 18, A 1090 Vienna, Austria
| | - Lin Li
- Department of Pediatrics, Medical University of Vienna, Austria Währinger Gürtel 18, A 1090 Vienna, Austria
| | - Harald Hoger
- Abteilung für Labortierkunde und - genetik, Medical University of Vienna, Brauhausgasse 34, A 2325 Himberg, Austria
| | - Arnold Pollak
- Department of Pediatrics, Medical University of Vienna, Austria Währinger Gürtel 18, A 1090 Vienna, Austria
| | - Gert Lubec
- Department of Pediatrics, Medical University of Vienna, Austria Währinger Gürtel 18, A 1090 Vienna, Austria.
| |
Collapse
|
186
|
Patil S, Rao RS, Amrutha N, Sanketh DS. Analysis of human papilloma virus in oral squamous cell carcinoma using p16: An immunohistochemical study. J Int Soc Prev Community Dent 2014; 4:61-6. [PMID: 24818098 PMCID: PMC4015165 DOI: 10.4103/2231-0762.131269] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Aims: The aim of this study is to evaluate the expression of human papilloma virus (HPV) in oral squamous cell carcinoma (OSCC) and to correlate the association of HPV in histological grades of OSCC using p16 (p16INK4a) immunohistochemistry (IHC). Subjects and Methods: This study consists of 30 histological diagnosed cases of OSCC (10-well-differentiated oral squamous cell carcinoma [WDOSCC], 10-moderately differentiated oral squamous cell carcinoma [MDOSCC] and 10-poorly differentiated oral squamous cell carcinoma [PDOSCC]). The sections were subjected to IHC procedure using p16. Two parameters in immunohistochemical p16 expression were evaluated by 3 observers based on the criteria by Galgano M. Tetal (2010) (a) percentage of p16 positive cases (b) pattern of p16 staining in various grades of OSCC. Statistical Analysis Used: Kappa test. Results: Totally, 30 samples of 0SCC, p16 positivity was noted in 26/30 (86.66%). Of 26 positive cases, p16 staining was positive in 7/10 (70%) of WDOSCC, 9/10 (90%) in MDOSCC and, 10/10 (100%) PDOSCC. Incidentally, we also found single dispersed cell staining in WDOSCC, patchy staining in MDOSCC and more diffuse staining pattern predominant in PDOSCC. Conclusions: Our study revealed an association between HPV and OSCC. Diffuse staining pattern was noted in PDOSCC, which in turn depicts the increase viral overload, which might have an influence on its aggressive behavior.
Collapse
Affiliation(s)
- S Patil
- Department of Oral Pathology, M.S. Ramaiah Dental College and Hospital, Mathikere, Bengaluru, Karnataka, India
| | - R S Rao
- Department of Oral Pathology, M.S. Ramaiah Dental College and Hospital, Mathikere, Bengaluru, Karnataka, India
| | - N Amrutha
- Department of Oral Pathology, M.S. Ramaiah Dental College and Hospital, Mathikere, Bengaluru, Karnataka, India
| | - D S Sanketh
- Department of Oral Pathology, M.S. Ramaiah Dental College and Hospital, Mathikere, Bengaluru, Karnataka, India
| |
Collapse
|
187
|
El Masri(y) WS, Patil S, Prasanna KV, Chowdhury JR. To cystoscope or not to cystoscope patients with traumatic spinal cord injuries managed with indwelling urethral or suprapubic catheters? That is the question! Spinal Cord 2014; 52:500. [DOI: 10.1038/sc.2014.37] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
188
|
Patil S, Trinidade A, Prinsley P, Hanif J. The use of an acrylic ear template in determining the optimal placement of a bone anchored hearing aid: our experience. Clin Otolaryngol 2014; 39:119-21. [PMID: 24636011 DOI: 10.1111/coa.12237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/11/2014] [Indexed: 11/29/2022]
Affiliation(s)
- S Patil
- Norfolk & Norwich University Hospital NHS Trust, Norwich, UK
| | | | | | | |
Collapse
|
189
|
Abstract
Molecular modelling studies were performed to identify the essential structural requirements of quinoline-based derivatives for improving their antimalarial activity. The developed CoMFA, CoMSIA and HQSAR models for a training set comprising 37 derivatives showed good statistical significance in terms of internal cross validation (q(2)) 0.70, 0.69 and 0.80 and non-cross validation (r(2)) 0.80, 0.79 and 0.80. Also, the predicted r(2) values (r(2)pred) of 0.63, 0.61 and 0.72 for a test set consisting of 12 compounds suggested significant predicting ability of the models. Structural features were correlated in terms of steric, electrostatic, hydrophobic, hydrogen bond donor and hydrogen bond acceptor interactions. Furthermore, the bioactive conformation was explored and explained by docking compounds #28, 32 and 40 into the active binding site of lactate dehydrogenase of Plasmodium falciparum. The QSAR models, contour map and docking binding affinity obtained could be successfully utilized as a guiding tool for the design and discovery of novel quinoline-based derivatives with potent antimalarial activity.
Collapse
Affiliation(s)
- R Sharma
- a School of Pharmacy , Devi Ahilya Vishwavidyalaya , Takshshila Campus, Madhya Pradesh , India
| | | | | |
Collapse
|
190
|
Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol 2014; 25:663-668. [PMID: 24458473 PMCID: PMC4229900 DOI: 10.1093/annonc/mdt578] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Revised: 11/12/2013] [Accepted: 12/03/2013] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The clinical trials that reported benefit of the rapalogs temsirolimus and everolimus in advanced renal cell carcinoma (RCC) were primarily conducted in patients with clear-cell histology (ccRCC). We assessed outcome with these mammalian target of rapamicin (mTOR) inhibitors in two subsets of kidney cancer: sarcomatoid variant ccRCC and nonclear-cell RCC. PATIENTS AND METHODS Baseline clinical features, information on prior treatment, and histologic subtypes were collected for patients previously treated with rapalogs for metastatic RCC of either nonclear phenotype or ccRCC with sarcomatoid features. Outcome was assessed centrally by a dedicated research radiologist for determination of tumor response, progression-free survival (PFS), and overall survival (OS). RESULTS Eighty-five patients received temsirolimus (n = 59) or everolimus (n = 26). Nonclear-cell phenotypes included papillary (n = 14), chromophobe (n = 9), collecting duct (n = 4), translocation-associated (n = 3), and unclassified (n = 32) RCC. Twenty-three patients had clear-cell histology with sarcomatoid features. The response rate in assessable patients (n = 82) was 7% (all partial responses); 49% of patients achieved stable disease, and 44% had progressive disease as their best response. Tumor shrinkage was observed in 26 patients (32%). Median PFS and OS were 2.9 and 8.7 months, respectively. Nine patients (11%) were treated for ≥1 year, including cases of papillary (n = 3), chromophobe (n = 2), unclassified (n = 3) RCC, and ccRCC with sarcomatoid features (n = 1). No tumor shrinkages were observed for patients with collecting duct or translocation-associated RCC. CONCLUSIONS A subset of patients with nonclear-cell and sarcomatoid variant ccRCC subtypes benefit from mTOR inhibitors, but most have poor outcome. Histologic subtype does not appear to be helpful in selecting patients for rapalog therapy. Future efforts should include the identification of predictive tissue biomarkers.
Collapse
Affiliation(s)
| | | | | | | | - A A Hakimi
- Surgery, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA
| | | | | | | | - S Patil
- Biostatistics and Epidemiology
| | | |
Collapse
|
191
|
Abstract
We describe a male patient who presented with sudden onset severe headache and right sided ptosis that was diagnosed to be secondary to pituitary apoplexy on the background of diabetes mellitus. This was complicated by left ventricular failure and acute coronary syndrome. The case highlights the importance of considering hypocortisolism/hypopituitarism as an important and rare precipitant of an acute coronary event as occurred in the case.
Collapse
Affiliation(s)
- Vishal Gupta
- Department of Endocrinology, Jaslok Hospital and Research Centre, Mumbai, India
| | - Sudarshan Patil
- Department of Resident Doctor in Endocrinilogy, Jaslok Hospital and Research Centre, Mumbai, India
| | - Dhiren Raval
- Department of Resident Doctor in Endocrinilogy, Jaslok Hospital and Research Centre, Mumbai, India
| | - Pratik Gopani
- Department of Medicine, Jaslok Hospital and Research Centre, Mumbai, India
| |
Collapse
|
192
|
Li L, Csaszar E, Szodorai E, Patil S, Pollak A, Lubec G. The differential hippocampal phosphoproteome of Apodemus sylvaticus paralleling spatial memory retrieval in the Barnes maze. Behav Brain Res 2014; 264:126-34. [PMID: 24509310 DOI: 10.1016/j.bbr.2014.01.047] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2013] [Revised: 01/28/2014] [Accepted: 01/31/2014] [Indexed: 12/23/2022]
Abstract
Protein phosphorylation is a well-known and well-documented mechanism in memory processes. Although a large series of protein kinases involved in memory processes have been reported, information on phosphoproteins is limited. It was therefore the aim of the study to determine a partial and differential phosphoproteome along with the corresponding network in hippocampus of a wild caught mouse strain with excellent performance in several paradigms of spatial memory. Apodemus sylvaticus mice were trained in the Barnes maze, a non-invasive test system for spatial memory and untrained mice served as controls. Animals were sacrificed 6h following memory retrieval, hippocampi were taken, proteins extracted and in-solution digestion was carried out with subsequent iTRAQ double labelling. Phosphopeptides were enriched by a TiO2-based method and semi-quantified using two fragmentation principles on the LTQ-orbitrap Velos. In hippocampi of trained animals phosphopeptide levels representing signalling, neuronal, synaptosomal, cytoskeletal and metabolism proteins were at least twofold reduced or increased. Furthermore, a network revealing a link to pathways of ubiquitination, the androgen receptor, small GTPase Rab5 and MAPK signaling as well as synucleins was constructed. This work is relevant for interpretation of previous work and the design of future studies on protein phosphorylation in spatial memory.
Collapse
Affiliation(s)
- Lin Li
- Department of Pediatrics, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | - Edina Csaszar
- Max F. Perutz Laboratories GmbH, Mass Spectrometry Facility, Dr. Bohr-Gasse 3, A-1030 Vienna, Austria
| | - Edit Szodorai
- Department of Pediatrics, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | - Sudarshan Patil
- Department of Pediatrics, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | - Arnold Pollak
- Department of Pediatrics, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
| | - Gert Lubec
- Department of Pediatrics, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
| |
Collapse
|
193
|
Giambarberi L, Patil S, Marano M, Chamberlain R. Burn Injury and Continuous Renal Replacement Therapy (CRRT): A Civilian Based Clinical Outcomes Study from a Level I Burn Center, 2007-2012. J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
194
|
Patil S, Chamberlain R. Does Primary Tumor Resection Method Influence Survival in Stage I/II Node Negative Lung Cancer Patients: A Comparative Analysis of Six Different Primary Tumor Resection Methods (SEER 1998-2009). J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
195
|
Nyberg C, Patil S, Chamberlain R. Gastrointestinal T-Cell Lymphomas: Does Underlying Enteropathy Effect Outcomes? A Population Based Comparison of 573 Patients from the Surveillance Epidemiology and End Result (SEER) Database (1973-2010). J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
196
|
Sidhu K, Patil S, Chamberlain R. Malignant Melanoma in African Americans: A Clinical Outcomes Based Study involving 1,106 African American patients from the Surveillance Epidemiology and End Result (SEER) Database (1988-2010). J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
197
|
Giambarberi L, Patil S, Chamberlain R. Eccrine Gland Carcinoma: A Population-Based Clinical Outcomes Study Involving 312 Patients from the Surveillance Epidemiology and End Result (SEER) Database (2000-2010). J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
198
|
Shrestha S, Patil S, Chamberlain R. Geographic And Regional Variations In The Use Of Sentinel Lymph Node Biopsy For Thin Melanoma: A Retrospective Study Of 24,101 Patients From The Surveillance, Epidemiology And End Result (SEER) Database (2003-2010). J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
199
|
Patil S, Chamberlain R. An Analysis of 4,433 Patients Undergoing Prophylactic Bilateral Mastectomy From National Inpatient Sample Database (2002 – 2009). J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
200
|
Patil S, Marano M, Houng A, Mansour H, Petrone S, Lee R, Chamberlain R. A Retrospective 17-Year Study Analyzing Outcome of Burn Injury in Elderly Patients (>70 Years). J Surg Res 2014. [DOI: 10.1016/j.jss.2013.11.1010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|